tickdelta
Sign in
Screener / SEC EDGAR /CIK 0000711404 /10-K filed Dec 5, 2025, compared with Dec 6, 2024 /Numbers from the XBRL of the 10-Ks
Health care peers:
CRLALGNILMNMTDCOOIDXX
Nasdaq Health care · Eye Care

Cooper Companies COO

COO quote by TradingView

The Cooper Companies, Inc. (Cooper, we or the Company), is a leading global medical device company focused on helping people experience life's beautiful moments. 10-K, Item 1

Headquarters
San Ramon, CA
Next results
around Dec 3, 2026
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $4.1B through the costs to a net profit of $374.9M · income statement of the 10-K

17% operating margin
Revenue to Gross profit: $2.7BRevenue to Cost of revenue: $1.4BGross profit to Operating profit: $682.9MGross profit to Operating expenses: $2.0BOperating profit to Net profit: $374.9MOperating profit to Tax & other: $308.0MOperating expenses to R&D: $172.2MOperating expenses to Sales, admin & other: $1.8B Revenue: $4.1B REVENUE $4.1B +5% Y/Y Gross profit: $2.7B · 66% margin GROSS PROFIT $2.7B 66% margin · +3% Y/Y Cost of revenue: $1.4B · 34% of revenue COST OF REVENUE $1.4B 34% of revenue Operating profit: $682.9M · 17% margin OPERATING PROFIT $682.9M 17% margin · −3% Y/Y Operating expenses: $2.0B · 49% of revenue OPERATING EXPENSES $2.0B 49% of revenue Net profit: $374.9M · 9% margin NET PROFIT $374.9M 9% margin · −4% Y/Y Tax & other: $308.0M · 8% of revenue TAX & OTHER $308.0M 8% of revenue R&D: $172.2M · 4% of revenue R&D $172.2M 4% of revenue Sales, admin & other: $1.8B · 45% of revenue SALES, ADMIN & OTHER $1.8B 45% of revenue
Gross profit $2.7B 66% margin · +3% Y/Y
Operating profit $682.9M 17% margin · −3% Y/Y
Net profit $374.9M 9% margin · −4% Y/Y
The full income statement, year by year

COO among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 59 peers the company is above, not a score.

Compare
Revenue growth: 5.1%, above 34% of 59 peers (their median 7.2%) REVENUE GROWTH 5.1% · above 34% Gross margin: 65.9%, above 56% of 50 peers (their median 64.2%) GROSS MARGIN 65.9% · above 56% Operating margin: 12.8%, above 46% of 50 peers (their median 13.7%) OPERATING MARGIN 12.8% · above 46% Net margin: 13.5%, above 59% of 59 peers (their median 9.5%) NET MARGIN 13.5% · above 59% FCF margin: 16.0%, above 53% of 55 peers (their median 15.2%) FCF MARGIN 16.0% · above 53% Return on capital: 4.2%, above 7% of 41 peers (their median 9.2%) RETURN ON CAPITAL 4.2% · above 7%
COO Peer median Below the median

What changed

4 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Dec 5, 2025 against Dec 6, 2024.

Risk factors
4 new paragraphs, nothing like them in the previous 10-K
10-K Item 1A
Receivables growing faster than revenue
Receivables +15.6% vs revenue +5.1% (+10.6 pts)
10-K · XBRL
Accounting checks
10 other checks clear, 1 worth a look
10-K · XBRL
Insiders
5 open-market buys in the last 90 days
Form 4
Filings
1 in the last 30 days
EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Receivables growing faster than revenue
    Receivables +15.6% vs revenue +5.1% (+10.6 pts)
  • Cash from operations $796.1M vs net income $374.9M (FY ending Oct 31, 2025)
9 more checks with nothing to note
  • Inventory +5.4% vs revenue +5.1% (+0.3 pts)
  • Same auditor in both 10-Ks: KPMG LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No longer listed: THE COOPER COMPANIES, INC. AND SUBSIDIARIES. Same as last year: Evaluation of the sufficiency of audit evidence over inventories and net sales
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

4 paragraphs in Risk Factors that were not in the 10-K filed Dec 6, 2024. Quoted as filed.

All 4 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Dec 6, 2024 10-K, ITEM 1A
    Changes in import and export policies, including new, increased or retaliatory tariffs, sanctions and countersanctions and customs restrictions by the U.S. and foreign governments, may disrupt our supply chain, adversely affect our relationships with customers and impact our competitiveness. It may be time-consuming and expensive for us…
  2. Item 1A · new paragraph · not in the 10-K filed Dec 6, 2024 10-K, ITEM 1A
    We also rely on third-party logistics providers for storage and distribution of our components and products. Because we have limited control over their operations, any disruption in these relationships—whether due to labor shortages, transportation delays, capacity constraints—could adversely affect our ability to deliver products to…
  3. Item 1A · new paragraph · not in the 10-K filed Dec 6, 2024 10-K, ITEM 1A
    Ongoing federal efforts to streamline government operations, including agency-wide efficiency programs, may further impact the resources and staffing levels available to the FDA. These changes could result in longer review times for our regulatory submissions. Any delays or disruptions in FDA review processes could adversely affect our…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$3.3B$3.6B$3.9B$4.1B
Net income$385.8M$294.2M$392.3M$374.9M
Operating cash flow$692.4M$607.5M$709.3M$796.1M
Free cash flow$450.4M$215.0M$288.1M$433.7M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$4.1B ▲ 5.1% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

1 filing in the last 30 days · SEC EDGAR

All filings

About the company

Cooper Companies, San Ramon, CA · from the 10-K filed Dec 5, 2025

The Cooper Companies, Inc. (Cooper, we or the Company), is a leading global medical device company focused on helping people experience life's beautiful moments. Headquartered in San Ramon, California, Cooper sells products in over 130 countries and positively impacts over fifty million lives each year. Cooper operates through two business segments, CooperVision and CooperSurgical. Our two business segments elevate standards of care with products and services in the fields of vision, fertility and women’s health. For financial information relating to these business segments, refer to Note 12. Business Segment Information in Item 8.

Headquarters
San Ramon, CA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
October 31
Last results
Sep 9, 2026
Incorporated in
DE

Email alerts

Sources

The 10-K filed Dec 5, 2025 (open at SEC), compared with the 10-K filed Dec 6, 2024. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/COO/export.csv") into a cell.